Monday 25 July 2011
AVI BioPharma - News Release
AVI BioPharma - News Release: "The Lancet Publishes Clinical Trial Data That Demonstrate Statistically Significant and Dose-Dependent Expression of Dystrophin in Duchenne Muscular Dystrophy Patients Treated With AVI BioPharma's Eteplirsen"
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment